Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma

针对 MYC 的工程外泌体可逆转原神经-间质转化并延长胶质母细胞瘤的生存期

阅读:10
作者:Amanda R Haltom, Wafa E Hassen, Janine Hensel, Jiha Kim, Hikaru Sugimoto, Bingrui Li, Kathleen M McAndrews, Meagan R Conner, Michelle L Kirtley, Xin Luo, Bingqing Xie, Olga V Volpert, Susan Olalekan, Natalia Maltsev, Anindita Basu, Valerie S LeBleu, Raghu Kalluri

Abstract

Dysregulated Myc signaling is a key oncogenic pathway in glioblastoma multiforme (GBM). Yet, effective therapeutic targeting of Myc continues to be challenging. Here, we demonstrate that exosomes generated from human bone marrow mesenchymal stem cells (MSCs) engineered to encapsulate siRNAs targeting Myc (iExo-Myc) localize to orthotopic GBM tumors in mice. Treatment of late stage GBM tumors with iExo-Myc inhibits proliferation and angiogenesis, suppresses tumor growth, and extends survival. Transcriptional profiling of tumors reveals that the mesenchymal transition and estrogen receptor signaling pathways are impacted by Myc inhibition. Single nuclei RNA sequencing (snRNA-seq) shows that iExo-Myc treatment induces transcriptional repression of multiple growth factor and interleukin signaling pathways, triggering a mesenchymal to proneural transition and shifting the cellular landscape of the tumor. These data confirm that Myc is an effective anti-glioma target and that iExo-Myc offers a feasible, readily translational strategy to inhibit challenging oncogene targets for the treatment of brain tumors.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。